2015 Meeting

Home / 2015 Meeting

PROGRAM

Program – Perfusion Downunder Winter Meeting 2015

 

 

Thursday 6th August 2015
08:30 – 12:30

 

Perfusion Downunder Collaboration Data Managers Meeting
14:00-15:30
Session 1:

Controlling the Red Stuff

“Artificial blood, factor concentrates and blood transfusion (great when used properly)”
Bruce D. Spiess – United States

“Outcomes of the ATACAS Trial”
Paul Myles -Australia

 

 
16:00-17:30 Session 2:

“Registries at Work

“A marriage of convenience to reduce transfusion”
Donald S. Likosky – United States

PDUC Current and New Initiatives
Rob Baker, Richard Newland – Australia

 
18:30-19:30 Session 3
Prof Merry Lecture
 

“Back to the Future”
Alan Merry – New Zealand

Friday 7th August 2015
08:00-010:00
Matters of Practice

Session 4:

Anticoagulation

“Anticoagulation for CPB – an imprecise science”
David Sidebotham – New Zealand

“Challenging the need for anticoagulation during ECMO”
Rinaldo Bellomo – Australia

“Heparin interactions with the Endothelial border- Glycocalyx”
Bruce D. Spiess – United States

Panel Discussion

 
10.30-12:00
Session 5:

Myocardial Protection

“Current Challenges: old hearts and meaningful outcomes”
“Protecting the senescent heart”
David McGiffin – Australia

“Patient -centres outcome measures in CV research”
Paul Myles – Australia

Panel Discussion

   
13:00-14:20
Session 6:

Oxygen Delivery

“Oxygen: The vital toxin!”
Bruce D. Spiess – United States

   
14:30-17:30
Session 7:


“Recipe for Success”
This multidisciplinary team tasking exercise from a parallel science combines verbal and non-verbal communication with technical and dexterity skills to create an end product that will be judged by experts in the field. 92

 

 
Saturday 8th August 2015
08:30-10:30
The Kidney the Gut and the lung

Session 8:

AKI and Cardiac Surgery

“Do diagnostic methods for AKI following cardiac surgery allow early intervention”
Rinaldo Bellomo – Australia

Normoxic vs Hyperoxic CPB: a RCT
Timothy Willcox – New Zealand

“PERForm: looking at AKI”
Donald S. Likosky – United States

Panel Discussion

   
11:00-12:30
Session 9:

Not in the Mainstream

“Pulmonary endarterectomy for CTEPH”
David McGiffin -Australia

“Continuous extracorporeal splanchnic support? “
Rinaldo Bellomo – Australia

Research Questions – Professorial Answers

   
13:30-15:00
Session 10:

Professorial Opinions


Why Clinical Trials Need to be Large and Rightly Sit at the Top of the Knowledge Hierarchy
Paul Myles – Australia

“The hierarchy of knowledge: the alternatives to RCT’s?”
Alan Merry -Nw Zealand

   
15:30-16:30
Session 11:

How to get the best out of PDUC

 

 

CALL FOR ABSTRACTS

Program – Perfusion Downunder Winter Meeting 2015

 

 

Call for Abstracts

You are invited to contribute a paper in any one of the themes outlined below. Abstracts must be submitted no later than the 1st June 2015.

Abstracts will be reviewed by the Abstract Grading Committee and may be accepted to any part of the meeting. The Scientific Program Committee reserves the right to assign accepted papers to any of the presentation formats. All presentation formats will form integral elements of the Scientific Program. An author may submit more than one abstract.

Follow the guidelines exactly as abstracts will not be retyped. Abstracts not complying with the guidelines may be withdrawn by the Scientific Program Committee.

Abstracts are invited on all aspects of Perfusion and related topics, research and clinical papers are welcome.

Papers will be presented as either free short (10 min) or long papers (15 min), or included as a focus point in a workshop.

In addition topics for inclusion in symposium and workshops are sought from participants at all times.

ABSTRACT DEADLINE: June 1, 2015

Abstract format instructions:

  • See the example below and follow the format exactly. Title, authors and institutions must be included in the document you submit.
  • Select arial font type size 10.
  • Abstract word limit is 250. The word limit relates only to the text of the abstract and does not include title, authors and institutions.
  • The complete abstract must be no more than 15cm wide and 12cm in length.
  • Use single line spacing.
  • TITLE should be in UPPER CASE, bold and at the top of the abstract.
  • The name of the presenting author to be indicated by an underlining (Michael McDonald CCP (Aust), Robert A Baker CCP (Aust), Timothy Willcox CCP (Aust)). The authors’ names (Christian Middle initial Surname, highest degree) should be followed by the institution, city, country (Sentence case).
  • Abbreviations may be used but must be spelt out in full at the first mention followed by the abbreviation in parentheses.
  • Please proof read your abstract carefully.

 

SAMPLE ABSTRACT
 

 

CLOPIDOGREL AND BLEEDING AFTER CORONARY ARTERY BYPASS GRAFT SURGERY
Jee-Yoong Leong MB BS, Vijit Cherian MCh, Robert A Baker PhD, John L Knight FRACS Cardiac and Thoracic Surgical Unit, Flinders Medical Centre, Bedford Park, South Australia, AUSTRALIABackground. Aspirin is the main antiplatelet medication used in patients with coronary artery disease, however there is growing evidence that the use of the more potent clopidogrel, on its own or in combination with aspirin, has superior outcomes. Clopidogrel has also been shown to increase the risk of bleeding after coronary artery bypass graft surgery, which is a significant cause of morbidity and mortality. We review the effect of the use of preoperative clopidogrel on bleeding-related complications after coronary artery bypass graft surgery in our institution. 

Methods. A retrospective analysis of all patients undergoing isolated coronary artery bypass graft surgery at the Flinders Medical Centre between July 2000 and June 2003. A comparison was made between patients who received preoperative clopidogrel with those who did not receive it. Also, a comparison was made between patients who were on clopidogrel only, aspirin only and neither medication.

Results. A total of 919 patients were identified, of which 88 (9.6%) were on preoperative clopidogrel. Clopidogrel recipients had a higher volume of drain loss, were transfused more units of blood, and had longer intensive care unit and postoperative hospital stays than patients not exposed to clopidogrel.

Conclusions. In the three year period studied, the data from our institution showed an increased risk of bleeding, blood transfusion and resource utilization in patients who were on clopidogrel before coronary artery bypass graft surgery.

 

 

Abstract Submissions

Electronic abstracts submission is preferred.
Email completed abstract (word document)
Include in your email the presenter’s name, address, and telephone number.

Email Submission to twillcox@perfusiondownunder.com

Speaker Timeline
Deadline for receipt of abstracts
June 1, 2015
Notification of acceptance
June 8, 2015

Speaker Expenses
All presenters are required to pay their own registration, accommodation and travel expenses.